Genetic Signatures (GSS) AGM 2025 Presentation summary

Business overview and technology

• Specializes in high-throughput syndromic PCR testing for infectious diseases, using proprietary 3base technology to streamline DNA analysis and enable rapid, accurate results.

• Operates globally with headquarters in Sydney and teams in Australia, EMEA, and the US, supported by channel partners in EMEA and Canada.

• 3base technology reduces genetic code complexity, enabling efficient pan-screening and greater resilience to genetic variation, with universal sample compatibility.

FY25 performance and market progress

• FY25 revenue grew 66% to $14.4m, with strong respiratory sales and a 208% year-on-year increase in enteric product sales.

• EMEA revenue rose 40% to $1.5m, driven by demand for enteric products and NHS adoption in the UK.

• US operations secured first commercial contracts and strengthened leadership, while Australia expanded business with existing customers.

Strategic direction and operational highlights

• New instrument strategy and strategic plan implemented in 2025, with leadership changes including a new CEO and Chair.

• Strategic pivot to automation solutions aims for faster development, lower costs, and enhanced automation, informed by fresh market assessments.

• Focus for FY26 includes unlocking UK opportunities, expanding US market penetration, and developing new automated solutions and software.